

Press Release

Abliva AB (publ), 556595-6538
30 April 2021 08:30:00 CEST - Lund,
Sweden



Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 32,601,360 as a result of a directed new issue of shares resolved by the Board of Directors on 30 March 2021 with authorization from the Annual General Meeting held on 20 May 2020.

Today, the last trading day of the month, there are in total 328,941,492 shares and votes in Abliva AB.

This information is information that Abliva AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-04-30 08:30 CEST.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>
Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg>

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Amended number of shares and votes in Abliva AB \(publ\)](#)

Abliva AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.

Press Release

Abliva AB (publ), 556595-6538
30 April 2021 08:30:00 CEST - Lund,
Sweden

The logo for Abliva AB, featuring the word "ABLIVA" in a bold, dark teal, sans-serif font. The letters are closely spaced and have a slightly irregular, hand-drawn appearance.

Abliva AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.